People: Affymax Inc (AFFY.O)

Summary

Name	Age	Since	Current Position
Hollings Renton	66	2009	Independent Chairman of the Board
Herbert Cross	40	2011	Chief Financial Officer
Kay Slocum	65	2006	Senior Vice President - Human Resources
Christine Conroy	51	2013	Senior Vice President - Regulatory Affairs and Quality Assurance
Karin Walker	39	2012	Chief Accounting Officer, Vice President - Finance
Tim Varacek		2013	Vice President - Sales and Account Management
Andrew Blair	49	2011	Vice President - Medical Affairs
Tracy Dunn	49	2002	Vice President - Intellectual Property and Legal Affairs
Carol Francisco	60	2008	Vice President - Biostatistics and Data Management
Michael Holfinger		2012	Vice President - Manufacturing and CMC Development
Krishna Polu	39	2011	Vice President - Clinical Development
Cynthia Smith	43	2012	Vice President - Market Access and Commercial Development
Sylvia Wheeler	51	2010	Vice President - Corporate Communications
Grace Shin	47	2008	General Counsel
Anne-Marie Duliege	52	2007	Chief Medical Officer
John Orwin	48	2013	Director
Kathleen LaPorte	51	2001	Independent Director
Keith Leonard	50	2007	Independent Director
Ted Love	53	2006	Independent Director
Daniel Spiegelman	54	2006	Independent Director
Christine van Heek	55	2007	Independent Director
John Walker		2006	Independent Director

» Insider Trading

Biographies

Name	Description
Hollings Renton	Mr. Hollings C. Renton is Independent Chairman of the Board of Affymax, Inc. He has served as a member of the Board since June 2009 and was appointed Chairman of the Board and Chairman of Nominating and Corporate Governance Committee in December 2009. Mr. Renton retired as Chairman of the board of directors at Onyx Pharmaceuticals, Inc. in March 2008, where he also served as President and Chief Executive Officer from 1993 and as director from 1992. Prior to joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company. He assumed that position in 1991 on Chiron's acquisition of Cetus Corporation, a biotechnology company, where he had been President since 1990 and Chief Operating Officer since 1987. He joined Cetus Corporation in 1981 and was Chief Financial Officer from 1983 to 1987. Mr. Renton currently serves as the co-chair and lead director of Portola Pharmaceuticals, a biopharmaceutical company, a member of the boards of directors of Rigel Pharmaceuticals, a biopharmaceutical company, and Cepheid Corporation, a molecular diagnostics company. Mr. Renton holds an M.B.A. from the University of Michigan and a B.S. in mathematics from Colorado State University.
Herbert Cross	Mr. Herbert C. Cross is Chief Financial Officer of Affymax, Inc. From November 2010 to March 2011, Mr. Cross served as Chief Accounting Officer and Vice President, Finance. From 2008 to 2010, Mr. Cross held multiple positions including Vice President, Finance for Facet Biotech Corporation, a public clinical-stage biotech company. From 2006 to 2008, Mr. Cross was corporate controller at PDL BioPharma, a public bio-pharmaceutical company. From 1999 to 2006, Mr. Cross held positions of increasing responsibility, including Vice President, Finance, at Neoforma, Inc., a public e-commerce software company. Mr. Cross also served as manager, Assurance and Business Advisory Services at Arthur Andersen, LLP, an independent registered public accounting firm. Mr. Cross holds a B.S. from the Haas School of Business at the University of California, Berkeley.
Kay Slocum	Ms. Kay Slocum has served as Senior Vice President - Human Resources of Affymax, Inc., since June 2006. From 2003 to 2006, Ms. Slocum served as a human resources consultant to the company. From 2001 to 2003, Ms. Slocum served as Vice President, Human Resources of Deltagen, Inc., a biotechnology company. She also served as a Vice President of Human Resources at Corixa Corporation (formerly Coulter Pharmaceutical), a biotechnology company. Earlier in her career, Ms. Slocum served as Manager of Corporate Employee Development for Varian Associates and Management Consultant for Coulter Corporation, a biotechnology company. Ms. Slocum holds an M.S. from Loyola University of Chicago and a B.A. from Southern Illinois University.
Christine Conroy	Dr. Christine Conroy, Pharm.D., has been appointed as the Senior Vice President - Regulatory Affairs and Quality Assurance of Affymax, Inc. Dr. Conroy had served as vice president, Corporate Quality and Regulatory Affairs for Affymax since December 2011. She served as vice president Regulatory Affairs and Clinical Quality Assurance from July 2007 to November 2011, and she held positions with increasing levels of responsibility in Regulatory Affairs from October 2004 to July 2007. Before joining Affymax, Dr. Conroy held various senior level positions in the regulatory departments of Genitope Corporation and Roche Global Development. She started her career in the pharmaceutical industry in 1989 at Syntex Laboratories, Inc. in the Medical Services Department. She earned her Pharm.D. from the University of Kansas, School of Pharmacy, and her B.S. in pharmacy from the University of Colorado, School of Pharmacy.
Karin Walker	Ms. Karin L. Walker, CPA, has been appointed as Chief Accounting Officer, Vice President - Finance of Affymax, Inc., effective October 02, 2012. Prior to joining Affymax, Ms. Walker served as vice president of finance and corporate controller at Amyris Inc., overseeing all accounting functions during the biotechnology company's transition from a development-stage company to a commercial organization. Before joining Amyris in 2009, Ms. Walker was the vice president of finance and corporate controller for CV Therapeutics, a biopharmaceutical company, where she built a robust finance function to support corporate growth and a number of complex transactions and strategic initiatives. Ms. Walker has also served in senior financial leadership roles at companies such as Knight Ridder Digital, Accellion and Niku Corporation. She earned a B.S. degree in business from the California State Polytechnic University, San Luis Obispo and is a certified public accountant (CPA).
Tim Varacek	Mr. Tim Varacek has been appointed as the Vice President - Sales and Account Management of Affymax Inc. Mr. Varacek had served as executive director, Sales and Account Management for Affymax since April 2011. Prior to joining Affymax, he served in various executive roles in Sales Management, and from January 2007 through March 2011 was responsible for managing national accounts for Amgen's nephrology franchise. During his tenure at Amgen, he also served in various management positions within Marketing and Sales Operations. Prior to Amgen, Mr. Varacek held positions in Sales, Sales Management and Sales Training at Bristol-Myers Squibb Inc. Mr. Varacek earned a B.S. in Biology from Binghamton University.
Andrew Blair	Dr. Andrew T. Blair, M.D., is Vice President - Medical Affairs of Affymax Inc. From 2008 to 2011, Dr. Blair was Vice President of Clinical Research for Proteon Therapeutics, a biotechnology company. From 2000 to 2008, Dr. Blair was Vice President of Clinical Research at Genzyme Corporation, a biotechnology company. He also led the US/Europe biomedical regulatory affairs and US Renal Medical Affairs group. From 1998 to 2000, Dr. Blair served as medical director for the end-stage Renal Disease Program at the University of Texas Medical Branch. Dr. Blair holds an M.D. from Rush Medical School in Chicago, Illinois and a B.S. in biology from the University of Illinois.
Tracy Dunn	Dr. Tracy J. Dunn, Ph.D., J.D., is Vice President - Intellectual Property and Legal Affairs of Affymax, Inc. From 1996 to 2002, Dr. Dunn served as Director of Intellectual Property at Aviron, a biotechnology company, and subsequently at Medimmune Vaccines, Inc., a biotechnology company. From 1991 to 1996, Dr. Dunn was a patent attorney at Townsend and Townsend and Crew in Palo Alto, California. Dr. Dunn holds J.D, Ph.D. and B.S. degrees from the University of Wisconsin, where she also completed a National Cancer Institute post-doctoral research fellowship.
Carol Francisco	Dr. Carol A. Francisco, Ph.D., is Vice President - Biostatistics & Data Management of Affymax, Inc. Prior to joining the Company, Dr. Francisco was Vice President of Biostatistics at ICON Clinical Research, Inc., a clinical research organization since 2000. From 1995 to 1999, Dr. Francisco held the position of Vice President, Biostatistics and Data Management at Pacific Research Associates, Inc., a contracts services company. From 1994 to 1995, Dr. Francisco served as Director, Biostatistics Department at Hoffman-La Roche, Inc., a pharmaceutical company. From 1986 to 1994, Dr. Francisco was Department Head, Biostatistics Department at Syntex Laboratories, Inc., a pharmaceutical company. Dr. Francisco holds a Ph.D. in statistics from Iowa State University, a M.A. in psychology from Western Washington University and a B.A. from Western Washington State College.
Michael Holfinger	Dr. Michael Holfinger, Ph.D., has been appointed as Vice President - Manufacturing and CMC Development of Affymax, Inc., effective July 09, 2012. Prior to joining Affymax, Dr. Holfinger held multiple positions at Pfizer, including most recently as senior manager in the API support team where he was responsible for change management, project management and technical support activities necessary to ensure an economical uninterrupted commercial supply of pharmaceutical ingredients for various products. Prior to Pfizer, Dr. Holfinger held multiple positions within the chemical process research and development group at Pharmacia Corporation, where he was responsible for implementation of commercial processes for the manufacturing of chemical intermediates and active pharmaceutical ingredients. From 1997-2004, he was a course instructor at the Pharmaceutical Education & Research Institute. He earned his Ph.D. in chemical engineering from the University of Wisconsin-Madison and received a dual B.S. degree in applied science, paper science, and engineering and chemistry at Miami University.
Krishna Polu	Dr. Krishna R. Polu, M.D., is Vice President - Clinical Development of Affymax, Inc. From 2009 to 2011, he served as Executive Director, Clinical Development. From 2007 to 2009, Dr. Polu was Executive Director, Global Development at Amgen, a biotechnology company. From 2003 to 2005, he was a clinical and research fellow at Harvard Medical School in the Renal Division at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Polu holds an M.D. from the University of Texas Health Science Center, San Antonio, and a B.A. in human biology from Stanford University.
Cynthia Smith	Ms. Cynthia Smith has been appointed as Vice President - Market Access and Commercial Development of Affymax, Inc., effective February 02, 2012. From 2008 to January 2012, she served as Executive Director, Public Policy, Payer Strategy and Operations. From 2000 to 2008, Ms. Smith held various positions at Merck & Co., Inc., a pharmaceutical company, including Executive Director, Medicare and Healthcare Systems Strategy, and management positions in Public Policy and Government Affairs. From 1995 to 2000, she was a Senior Analyst, Healthcare Policy for the White House Office of Management and Budget. She earned her M.B.A. in finance from the Wharton School of the University of Pennsylvania, an M.S. in public policy from the Eagleton Institute of Politics at Rutgers University and a B.A. in communications from the University of North Carolina, Chapel Hill.
Sylvia Wheeler	Ms. Sylvia Wheeler is Vice President - Corporate Communications of Affymax, Inc., since April 2010. Prior to that served as executive director, Corporate Communications since January 2007. From 2004 to 2007, Ms. Wheeler served as senior director, Corporate Communications, for Depomed, Inc., a specialty pharmaceutical company. From 2000 to 2003, Ms. Wheeler served as director, Corporate Communications, for Cerus Corporation, a biomedical products company. From 1997 to 2000, Ms. Wheeler served as director, Corporate Communications, for Coulter Pharmaceutical, Inc.. From 1995 to 1997, she served as director, corporate relations and planning, Connetics Corporation, a specialty pharmaceutical company. Ms. Wheeler serves as a member of the board of directors for the National Kidney Foundation Northwestern U.S. Division. She holds an M.B.A. from the University of San Francisco and a B.A. in Biology from San Francisco State University.
Grace Shin	Ms. Grace U. Shin, J.D., is General Counsel of Affymax, Inc., since June 2008. And prior to that served as Vice President, Legal Affairs and Corporate Counsel since October 2006. From 2000 to April 2006, Ms. Shin served as Vice President of Legal Affairs and Corporate Counsel to FibroGen, Inc., a biotechnology company, and from May 1997 to 2000 held the position of Corporate Counsel. From 1992 to 1997, Ms. Shin was a corporate attorney at Pacific Gas & Electric Company, a public utility. From 1989 to 1992, Ms. Shin was a business associate at Cooley Godward LLP, a law firm. Ms. Shin holds a J.D. from the University of Michigan Law School and a B.A. from the University of Michigan School of Business Administration.
Anne-Marie Duliege	Dr. Anne-Marie Duliege, M.D., M.S., is Chief Medical Officer of Affymax, Inc. She has served as Chief Medical Officer since July 2007 and prior to that served as Vice President, Clinical, Medical and Regulatory Affairs since 2004. Since 1998, Dr. Duliege has also practiced medicine at the Lucille Packard Children's Hospital at Stanford University Medical Center. From 1992 to 2004, Dr. Duliege served in various positions at Chiron Corporation, a biotechnology company, most recently as Senior Medical Director. Dr. Duliege holds an M.D. and M.S. from Paris Medical School and an M.S. from Harvard School of Public Health.
John Orwin	Mr. John A. Orwin is Director of Affymax Inc. He served as Chief Executive Officer of the Company until May 15, 2013. From April 2010 to January 2011, he served as President and Chief Operating Officer. From 2005 to 2010, Mr. Orwin served as Vice President and then Senior Vice President, BioOncology Business Unit, at Genentech, Inc. where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech's oncology portfolio in the United States. From 2001 to 2005, Mr. Orwin served in various executive level positions at Johnson & Johnson overseeing oncology therapeutic commercial and portfolio expansion efforts in the United States. He has also held senior marketing and sales positions at Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation. Mr. Orwin serves as a member of the board of directors of NeurogesX, a biopharmaceutical company. Mr. Orwin holds an M.B.A. from New York University and a B.A. from Rutgers University.
Kathleen LaPorte	Ms. Kathleen D. LaPorte has served as Independent Director of Affymax, Inc., since 2001. She is a member of the Audit Committee since 2011. From 2003 to 2011, Ms. LaPorte also served as a member of the Compensation Committee of the Board (the "Compensation Committee"). Since 2011, Ms. LaPorte has served as Venture Partner of New Leaf Venture Partners, a venture capital firm of which she was a founding partner. She also served as Partner of New Leaf Venture Partners from 2005 to 2011. Ms. LaPorte has also been Managing Director of HealthTech Capital, an angel investment group, since 2010. From 1994 to 2005, Ms. LaPorte served as General Partner of Sprout Group, a venture capital firm, which she joined in 1993. Sprout Group was one of several venture firms involved in the spin out of Affymax from GlaxoSmithKline in 2001, and, in the Company's early stages of formation, Ms. LaPorte acted as an officer in various capacities until February 2002. From 1987 to 1993, Ms. LaPorte served as an employee at Asset Management Company, a venture capital firm, most recently as a Principal. Ms. LaPorte currently serves as a member of the boards of directors of Transcept Pharmaceuticals, Inc., a pharmaceutical company, and several privately held companies. Previously, Ms. LaPorte served as a member of the board of directors of ISTA Pharmaceuticals, Inc., a pharmaceutical company, Adeza Biomedical Corporation, a biomedical company, eHealth, Inc, an on-line health insurance brokerage company, and VNUS Medical Technologies, a medical device company. Ms. LaPorte holds an M.B.A. from Stanford University and a B.S. from Yale University.
Keith Leonard	Mr. Keith R. Leonard, Jr., has served as Independent Director of Affymax, Inc., since December 2007. He is a member of the Compensation Committee since May 2011. From March 2008 until May 2011, Mr. Leonard also served as a member of the Audit Committee. Mr. Leonard is currently President and Chief Executive Officer and a director of Kythera Biopharmaceuticals, a biopharmaceutical company he founded in 2005. Prior to Kythera, Mr. Leonard served 13 years in various roles at Amgen, Inc., a biotechnology company, most recently as Senior Vice President, Amgen Europe from 2001 to 2004. Until February 2011, Mr. Leonard served on the board of directors of ARYx Therapeutics, Inc., a biopharmaceutical company. Mr. Leonard holds an M.B.A. from the University of California, Los Angeles; an M.S. in engineering from the University of California, Berkeley; a B.A. in history from the University of Maryland; and a B.S. in engineering from the University of California, Los Angeles.
Ted Love	Dr. Ted W. Love, M.D., is Independent Director of Affymax, Inc., since June 2006. He is a member of the Audit Committee of the Board (the "Audit Committee") since July 2006. In 2010, Dr. Love joined Onyx Pharmaceuticals, a biopharmaceutical company, as Executive Vice President, Research and Development. From 2001 to 2009, Dr. Love served as the President, Chief Executive Officer and member of the board of directors of Nuvelo, Inc., a biopharmaceutical company, and as Chairman of Nuvelo's board of directors from 2005 to 2009, prior to its merger with ARCA biopharma, Inc. From 1998 to 2001, Dr. Love served as Senior Vice President of Development at Theravance, Inc. (formerly Advanced Medicine, Inc.), a biopharmaceutical company. From 1992 to 1998, Dr. Love served as a research physician and Vice President of Product Development at Genentech, Inc., a biotechnology company. Dr. Love also serves as a member of the boards of directors of Santarus, Inc., a pharmaceutical company, and ARCA biopharma, Inc., a biopharmaceutical company. Dr. Love holds an M.D. from Yale Medical School and a B.A. from Haverford College.
Daniel Spiegelman	Mr. Daniel K. Spiegelman has served as Independent Director of Affymax, Inc., since September 2006. Mr. Spiegelman has served as the Chairman of the Audit Committee since December 2006. Mr. Spiegelman has served as Chief Executive Officer of Filtini, Inc., a private company developing circulating tumor cell diagnostic devices, since September 2009, and has served as Chief Financial Officer and director of Rapidscan Pharma Solutions, Inc., a private company developing diagnostic technologies, since 2009. From 1998 to 2009, Mr. Spiegelman served in various positions, most recently as Senior Vice President and Chief Financial Officer, of CV Therapeutics, Inc., a biopharmaceutical company, which was acquired by Gilead Sciences, Inc. From 1992 to 1998, Mr. Spiegelman was an employee at Genentech, Inc., most recently as Treasurer. Mr. Spiegelman also serves as a member of the boards of directors of Anthera Pharmaceuticals, Inc., a biopharmaceutical company, Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, Omeros Corporation, a biopharmaceutical company and Oncothyreon, Inc., a biotechnology company. Mr. Spiegelman holds an M.B.A. and a B.A. from Stanford University.
Christine van Heek	Ms. Christine van Heek has served as Independent Director of Affymax, Inc., since December 2007. She is a member of the Nominating and Corporate Governance Committee of the Board (the "Nominating and Corporate Governance Committee") since March 2008 and as a member of the Compensation Committee since May 2011. Ms. van Heek is currently Managing Partner of BIO POINT Group, a business development consulting company she founded in 2003. From 1991 to 2003, Ms. van Heek served in various roles at Genzyme, Inc., a biotechnology company, most recently as Corporate Officer and President, Therapeutics Division. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA. Ms. van Heek holds an M.B.A. from Lindenwood University in St. Louis and a B.S.N. from the University of Iowa.
John Walker	Mr. John P. Walker has served as Independent Director of Affymax, Inc., since April 2006. He has been a member of the Nominating and Corporate Governance Committee since July 2006, and a member of the Compensation Committee since 2007. Mr. Walker has served as the Chairman of the Compensation Committee since January 2008. From July 2006 until March 2008, Mr. Walker also served as a member of the Audit Committee. Mr. Walker is currently a Managing Director of Four Oaks Partners, a life sciences transaction advisory firm, which he co-founded in March 2012. From February 2009 until July 2010, Mr. Walker was the Chief Executive Officer at iPierian, Inc, a company focused on the use of inducible stem cells for drug discovery. From 2006 until 2009, Mr. Walker served as the Chairman and Chief Executive Officer of Novacea, Inc., a pharmaceutical company, which merged with Transcept Pharmaceuticals, Inc., a pharmaceutical company, in January 2009. Since 2001, Mr. Walker, acting as a consultant, was Chairman and Interim Chief Executive Officer at Kai Pharmaceuticals, a pharmaceutical company, Guava Technologies, a biotechnology company, Centaur Pharmaceuticals, Inc., a pharmaceutical company, and Chairman and Chief Executive Officer of Bayhill Therapeutics, a biotechnology company. From 1993 until 2001, Mr. Walker was the Chairman and Chief Executive Officer of Arris Pharmaceutical Corporation, a pharmaceutical company, and its successor, Axys Pharmaceuticals Inc. Mr. Walker currently serves on the boards of directors of several privately held biotechnology companies, and is also on the board of directors of Packard Children's Hospital at Stanford. Mr. Walker is a graduate of the Advanced Executive Program at The Kellogg School of Management at Northwestern University and holds a B.A. from the State University of New York at Buffalo.

Basic Compensation

Name	Fiscal Year Total
Hollings Renton	--
Herbert Cross	636,456
Kay Slocum	--
Christine Conroy	--
Karin Walker	--
Tim Varacek	--
Andrew Blair	--
Tracy Dunn	--
Carol Francisco	--
Michael Holfinger	--
Krishna Polu	--
Cynthia Smith	--
Sylvia Wheeler	--
Grace Shin	--
Anne-Marie Duliege	663,835
John Orwin	3,012,670
Kathleen LaPorte	--
Keith Leonard	--
Ted Love	--
Daniel Spiegelman	--
Christine van Heek	--
John Walker	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Hollings Renton	0	0
Herbert Cross	0	0
Kay Slocum	0	0
Christine Conroy	0	0
Karin Walker	0	0
Tim Varacek	0	0
Andrew Blair	0	0
Tracy Dunn	0	0
Carol Francisco	0	0
Michael Holfinger	0	0
Krishna Polu	0	0
Cynthia Smith	0	0
Sylvia Wheeler	0	0
Grace Shin	0	0
Anne-Marie Duliege	26,583	401,354
John Orwin	0	0
Kathleen LaPorte	0	0
Keith Leonard	0	0
Ted Love	0	0
Daniel Spiegelman	0	0
Christine van Heek	0	0
John Walker	0	0

Insider Trading

Name	Shares Traded	Price
KNAPP JEFFREY H	313	$7.04
KNAPP JEFFREY H	1,000	$7.99
KNAPP JEFFREY H	2,328	$15.76
KNAPP JEFFREY H	1,015	$6.23
ORWIN JOHN A	6,366	$18.81
ORWIN JOHN A	2,200	$5.83
ORWIN JOHN A	4,166	$6.90
DULIEGE ANNE MARIE	5,000	$0.00
ORWIN JOHN A	16,000	$0.00
CROSS HERBERT C	5,000	$0.00
KNAPP JEFFREY H	5,000	$0.00
KNAPP JEFFREY H	1,016	$6.23
KNAPP JEFFREY H	1,000	$7.99
KNAPP JEFFREY H	312	$7.04
KNAPP JEFFREY H	583	$10.99
KNAPP JEFFREY H	6,661	$21.25
KNAPP JEFFREY H	3,750	$18.84
KNAPP JEFFREY H	1,000	$7.99
KNAPP JEFFREY H	313	$7.04
KNAPP JEFFREY H	1,047	$6.23
KNAPP JEFFREY H	6,694	$22.31
KNAPP JEFFREY H	584	$10.99
KNAPP JEFFREY H	3,750	$18.84
LAPORTE KATHLEEN D	5,000	$22.72
LAPORTE KATHLEEN D	2,500	$14.24

» Full list on Insider Trading

People: Affymax Inc (AFFY.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: